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MaWhile acute myocardial infarction mortality declines, patients continue to face reinfarction and/or heart failure. The
immune system, which intimately interacts with healthy and diseased tissues through resident and recruited leukocytes,
is a central interface for a global host response to ischemia. Pathways that enhance the systemic leukocyte supply may be
potential therapeutic targets. Pre-clinically, imaging helps to identify immunity’s decision nodes, which may serve as such
targets. In translating the rapidly-expanding pre-clinical data on immune activity, the difﬁculty of obtaining multiple
clinical tissue samples from involved organs is an obstacle that whole-body imaging can help overcome. In patients,
molecular and cellular imaging can be integrated with blood-based diagnostics to assess the translatability of discoveries,
including the activation of hematopoietic tissues after myocardial infarction, and serve as an endpoint in clinical trials. In
this review, we discuss these concepts while focusing on imaging immune activity in organs involved in ischemic heart
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ABBR EV I A T I ON S
AND ACRONYMS
AMI = acute myocardial
infarction
CMR = cardiac magnetic
resonance
FDG = ﬂuorodeoxyglucose
IVM = intravital microscopy
PET = positron emission
tomography
USPIO = ultrasmall
superparamagnetic iron
oxide nanoparticles
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1584atherosclerosis and its comorbidities, clinical
progress now appears to be within reach. The
ﬁrst clinical trials investigating neutralizing
interleukin-1b (2) and modulating cellular
immune responses with low-dose metho-
trexate (3) are bellwethers for immune tar-
geting strategies in cardiovascular medicine.
THE CELLULAR IMMUNE SYSTEM IN
HEALTHY CARDIOVASCULAR ORGANS
The cardiovascular system is in constant,
intimate contact with immune cells, and doesfar more than transport circulating leukocytes and
cytokines. The vascular endothelial layer regulates
cell recruitment, signaling the stroma’s status to
circulating leukocytes via expression of adhesion
molecules and chemokines. Some immune cells,
including monocytes and neutrophils, patrol the
endothelium by crawling along or below its surface
(4–7). The endothelium is less of a barrier than pre-
viously thought: even in steady state, leukocytes
extravasate. Extravasation is subject to circadian
rhythms and may be partly regulated by nervous
signals (8). There is a surprisingly dense network of
tissue-resident leukocytes (9) in healthy vascular (10)
and myocardial tissue (11–14). Tissue-resident mac-
rophages are numerous and create a close-knit
network interspersed within the stroma. The high
number and organization of the cells, whose delicate
dendrites increase their reach and surface area, could
only be observed using the recently-devised tech-
nique of applying ﬂuorescence microscopic imaging
to thicker cardiac tissue sections (Figure 1). Expres-
sion of bright ﬂuorescence reporters in tissue-
resident macrophages revealed their number and
organization in the hearts of transgenic mice (12,14).
These cells are assumed to pursue sentinel functions
and support stromal cells’ tissue-speciﬁc tasks.
THE CELLULAR IMMUNE SYSTEM
IN ATHEROSCLEROSIS
Immune cell phenotype, number, and function in the
arterial wall change drastically in atherosclerosis.
Macrophages increase 20-fold in apolipoprotein E/
mice on a Western diet (10). Pre-clinical (15,16) and
clinical (17) studies show that activated endothelium
recruits monocytes, neutrophils, and lymphocytes,
even in the early stages of atherosclerosis (1,18,19).
Innate immune cells should remove cholesterol de-
posits from the intima, but they fail to do so, and
instead give rise to inﬂamed plaques. Monocytes
adopting inﬂammatory phenotypes differentiate intomacrophages and foam cells and engage in tissue
destruction by releasing cytokines and proteases that
weaken the stromal architecture (20). Prototypical
sequelae include plaque rupture and erosion, with
subsequent thrombotic stenosis or occlusion of ar-
teries and tissue ischemia. Dendritic cells and
lymphocytes also participate in disease progression
or regulation (21). Presentation of autoantigens, in-
cluding oxidized lipoproteins, to lymphocytes may
trigger their proliferation and activation (18). B cells
pursue regulatory functions (21), for instance, by
instructing increased innate immune cell production
(22). In addition, regulatory T cells have protective
roles (23). Imaging data support many of these
insights. Pre-clinical optical imaging, especially
intravital microscopy (IVM), shows immune cell in-
teractions with stromal cells and with each other. In
the past, the rigorous and rapid motion of cardio-
vascular organs posed a problem for IVM; however,
recent progress in tissue stabilization, gating image
acquisition, and/or reconstruction has overcome
these hurdles (24,25) (Figure 1).
THE IMMUNE SYSTEM IN AMI
Whereas atherosclerotic lesions develop due to
chronic low-grade inﬂammation, the ischemic events
triggered by atherosclerosis induce high-amplitude
acute inﬂammatory responses. In patients and in
mice, AMI triggers robust blood leukocytosis (1).
These events have recently been studied in more
detail, and we now understand which immune cells
or cell subsets react to MI. The changes observed in
blood are the “tip of the iceberg”: circulating com-
ponents mirror systems-wide increases in immune
cell numbers and activity in the ischemic myocar-
dium, the remote nonischemic myocardium, non-
culprit plaques, heart-draining lymph nodes, the
spleen, and bone marrow. Sampling blood reveals
immune cell migration from storage or production
sites to the atherosclerotic plaque or failing myocar-
dium. Tissue is more difﬁcult to assay than blood.
Imaging and ﬂow cytometry of digested myocardium
and arteries enable quantitative approaches and
provide the cell recruitment timeline after ischemic
injury. The most numerous and fastest responders are
innate immune cells. Neutrophils and the inﬂamma-
tory monocyte subset begin to inﬁltrate the distressed
myocardium within the ﬁrst 30 min after ischemia
onset (24), while resident macrophages disappear
(14), most likely due to local death or emigration. The
neutrophil response wanes quickly, and inﬂamma-
tory monocytes continue to inﬁltrate at high rates for
the ﬁrst 4 days after ischemia (11). The number of
FIGURE 1 Preclinical Cardiovascular Immune Imaging
(A) Confocal microscopy of sympathetic nerve ﬁbers in the bone marrow (48). (B) Intravital microscopy (IVM) of adoptively-transferred, ﬂuorescently-labeled he-
matopoietic progenitor cells in the bone marrow (48). (C) IVM of a patrolling monocyte (74). (D) IVM of a departing splenic monocyte (43). (E) Bioluminescence imaging
of cell cycling in the bone marrow after ischemic injury (48). (F and G) IVM of the beating mouse heart visualizes leukocytes in myocardial capillary. A tissue stabilizer is
also shown (25). (H) Positron emission tomography / magnetic resonance imaging of macrophages in atherosclerotic plaque using isotope-labeled nanoparticles (75). (I)
Protease ﬂuorescence tomography in a mouse with atherosclerosis (37). (J) Positron emission tomography/magnetic resonance imaging of macrophages in a mouse with
myocardial infarction using isotope-labeled nanoparticles (Nahrendorf, unpublished data, 2012). HSC ¼ hematopoietic stem cells; SNS ¼ sympathetic nervous system.
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1585immune cells increases by 2 orders of magnitude in
ischemic versus steady-state myocardium. Interest-
ingly, recruited myeloid cells only survive in ischemic
tissue for an average of 20 h in the mouse (26),
highlighting the high turnover of cells in the infarct.
Inﬂammatory monocytes, which differentiate to M1-
like macrophages, pursue proteolysis of pre-existing
extracellular matrix and phagocytosis of dying cells.
After 4 days, there is a transition to a second, less
inﬂammatory phase (11), during which low numbers
of patrolling Ly6Clow monocytes are also recruited,and Ly6Chigh monocytes give rise to macrophages
with fewer inﬂammatory functions (27). Macrophages
now support tissue rebuilding; crosstalk to stromal
cells via vascular endothelial growth factor and
transforming growth factor b supports angiogenesis
and production of new extracellular matrix, respec-
tively. These 2 phases were discovered in the mouse
(11,28), but have since been observed in the blood (29)
and heart (30) of humans with AMI. If 1 of these
phases is compromised, for example, by an over-
zealous supply of inﬂammatory cells delaying the
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deteriorates and heart failure occurs (31). In patients,
post-MI blood monocyte levels predict cardiovas-
cular mortality (32). When viewed together with the
pre-clinical data, this association underscores the
putative role of innate immune cells as a therapeutic
target. Lymphocytes also participate in the post-MI
immune response, albeit at lower numbers. Regu-
latory T cells hasten the transition from the in-
ﬂammatory to the resolution phase by supporting a
switch toward M2-type macrophage phenotypes (33),
whereas B cells regulate the migratory patterns of
myeloid cells, including their release from bone
marrow (34).
SOURCES OF INNATE IMMUNE CELLS
Neutrophils and monocytes, the progenitors of in-
ﬂammatory macrophages in the infarct and athero-
sclerotic lesions, are made in the bone marrow (35).
The spleen also has myelopoietic functions in mice
with atherosclerosis (36) and after MI (26). Before
birth, the spleen and liver are sources of blood cells,
but thereafter, they cease hematopoietic activity in
the steady state. In certain diseases (at least in ro-
dent models), the spleen regains the capacity to
produce innate immune cells (1). Fluorescence im-
aging indicates that this occurs after hematopoietic
progenitor and stem cells transfer from the bone
marrow to the spleen (37). Although we are begin-
ning to understand the signals that lead to bone
marrow release and splenic seeding of hematopoietic
stem cells in mice, translational data remain scarce,
and are mostly limited to cell numbers in blood
(38,39). Interestingly, recent data obtained on tissue-
resident macrophages, that is, the cells that inhabit
the myocardium and vascular wall in the steady
state, suggest that many of these cells derive not
from blood monocytes, but rather from proliferating
macrophages in situ (13,14). Likewise, plaque mac-
rophages, which derive from recruited blood mono-
cytes, proliferate locally (40). The signals that
regulate cell supply are of interest for future thera-
peutic strategies because locally-sourced tissue-
resident macrophages may have different functions
than macrophages derived from the bone marrow or
spleen. Once we understand the pathways involved
in the information transfer from ischemic tissue to
the sites of leukocyte production, we can begin to
explore whether these pathways provide opportu-
nities to therapeutically target inﬂammation in
ischemic heart disease. One such pathway may be
the nervous system, which instructs hematopoietic
tissues in AMI (37).CHANCES AND CHALLENGES
Pre-clinical data provide a convincing rationale for
the causal role of innate immunity in disease pro-
gression, including atherosclerotic lesion growth and
post-ischemic complications, such as reinfarction
and heart failure. However, this knowledge has not
yet been harnessed to develop therapeutics. Dis-
tinct components of the immune system may either
preserve health (e.g., tissue-resident macrophages,
regulatory T cells) or promote disease (e.g., inﬂam-
matory monocyte-derived plaque macrophages,
innate response activator B cells). Whether their
functions are beneﬁcial or not may also depend on
the disease phase. Thus, broad immune pathway
targeting is unlikely to confer therapeutic beneﬁts, a
lesson learned from trials inhibiting tumor necrosis
factor in heart failure (e.g., the RECOVER and RE-
NAISSANCE trials [41]). In addition, immune func-
tions that are harmful for cardiovascular health may
be essential for defense against microbes. Devel-
oping immune-targeted therapeutics in ischemic
heart disease involves identifying suitable pathways
in mice, pre-clinical testing of whether the path-
way can be neutralized without causing collateral
damage, translational studies identifying similarly
relevant pathways in humans, and, ﬁnally, clinical
trials.
We argue that this long drug discovery path can be
negotiated more efﬁciently with the help of immune
system imaging, especially of immune cells, their
subsets, and their migration, production, and func-
tion. More speciﬁcally, imaging can report on stromal
immune cell activity in multiple tissues in living pa-
tients. In addition to coronary imaging (recently
reviewed by Garcia-Garcia et al. [42]), as comorbid-
ities aggravate cardiovascular disease via inﬂamma-
tory crosstalk, noncardiovascular organs may also be
of interest and, therefore, constitute another putative
therapeutic target. To understand systems-wide im-
mune action after MI, particularly connections of
cardiovascular with immune and hematopoietic or-
gans, future imaging studies should focus not only on
the ischemic heart, but also on remote myocardium,
local lymph nodes, nonculprit atherosclerotic lesions,
spleen, and bone marrow, and integrate these data
with analysis of blood. Ideally, molecular imaging
could also probe modes of information transfer, such
as the nervous or endocrine systems, which regulate
immune cell production, storage, migration, and
function. While it is impossible to attain these
comprehensive data through patient biopsies,
cellular and molecular whole-body imaging reports
on many tissues simultaneously. These methods can
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imaging in clinical trials, and guide individualized
therapy.
Currently, large-scale cardiovascular trials use
survival as a hard endpoint. Although this is the ul-
timate test of a therapy’s value, it is so expensive that
these trials often become unaffordable (43). Each
failed trial increases research and development costs,
ultimately reducing the capacity to pursue such pro-
jects. Companion imaging may provide faster, much
more cost-effective surrogate endpoints that also
report on drug action. Although survival endpoint
data are likely necessary, imaging trials, which can be
much smaller, may provide a cost-effective interme-
diate step with a higher tolerance for failure. In the
following text, we describe immune system imaging
that could facilitate development of ischemic heart
disease therapeutics.
HOW CAN PRE-CLINICAL IMAGING
ACCELERATE PROGRESS?
Over the last 2 decades, pre-clinical imaging has
made astounding progress. Optical imaging led to
many catalyst tools that allowed us to uncover im-
mune cell birth, activity, and function. Speciﬁcally,
the combination of ﬂuorescent reporters with IVM-
facilitated discoveries such as the splenic monocyte
reservoir (44) and patrolling leukocytes (4,7), i.e.,
monocytes and neutrophils that crawl along the
endothelium in small vessels. Multicolor imaging
revealed the interaction of leukocytes with each
other during antigen presentation (45) or with stro-
mal cells and pathogens. These tools were originally
developed for observing cells in steady state or ma-
lignant disease, but are now being adapted for
cardiovascular applications. Even in immobile solid
tumors, small movements, for instance due to re-
spiration, are ampliﬁed during cellular-scale imaging.
The rigorous cardiovascular motion caused by cardiac
contractions and pulsatile blood ﬂow is a formidable
hurdle that has been overcome by combining tissue
stabilizers, electrocardiographic gating, and post-
processing algorithms. The result is that for the ﬁrst
time, we can watch cells rolling though myocardial
capillaries, inﬁltrating the infarct or atherosclerotic
plaque, and interacting with each other in the
vascular wall (24,25,45–47) (Figure 1). This is an
important step toward the goal of therapeutically
interfering with immune cell migration or antigen
presentation. Another example of innovation through
imaging involves serial observation of hematopoietic
stem cells (48) that give rise to inﬂammatory leuko-
cytes and do so at increased rates after organischemia (49) (Figure 1). On the whole-animal scale,
optical imaging is used to study the time course of
pathway activation (50) and disease progression,
for instance, by serially probing protease activity,
adhesion molecules, or immune cell abundance in
inﬂamed tissue (37). Of particular value are quanti-
tative methods, such as ﬂuorescence tomography
and bioluminescence imaging. Both detect photons
that arise from either laser-excited ﬂuorochromes (51)
or reporter gene activation of bioluminescent lucif-
erin (52). Pre-clinical work on translatable imaging
methods, mostly magnetic resonance and nuclear
imaging, has led to a number of promising
candidate technologies (53) now awaiting ﬁrst-
in-human trials. Typical imaging targets in studying
ischemic heart disease are macrophages, adhesion
molecules, and leukocyte receptors (54). Cell-speciﬁc
expression of ﬂuorescent or bioluminescent re-
porters enables the study of speciﬁc immune cells
over time and, in the case of dual reporters, cell
interactions.
HOW CAN CURRENT CLINICAL IMAGING
ACCELERATE TRANSLATION?
Several agents that target immune activity have
already been translated, and other agents initially
developed for different applications are being repur-
posed successfully. One repurposed agent is ul-
trasmall superparamagnetic iron oxide nanoparticles
(USPIO), which are sensitive because 1 particle dras-
tically changes the behavior of many surrounding
protons that give rise to magnetic resonance imaging
signal. Extensive testing in mice showed that USPIO
localize within plaque and infarct macrophages (55), a
result later conﬁrmed in patients after carotid end-
arterectomy (56). Two recent trials used USPIO to
image the inﬂammatory response in AMI patients.
Before and 48 h after injection of ferumoxytol, T2*
value assessed in the infarcted and remote myocar-
dium indicated signiﬁcant nanoparticle accumulation
(57,58). One study also reported a signal change in the
spleen (57). In conjunction with earlier mouse studies
(59), these results indicate that ferumoxytol is useful
for imaging macrophages in the arterial wall and
myocardium. Low signal on T2*-weighted CMR can
also arise from hemorrhage, motion, and ﬂow-related
artifacts. These limitations can be addressed with
pre-injection scans and positive-contrast iron imag-
ing techniques (55).
The nuclear imaging modality positron emis-
sion tomography (PET) has a quantitative advan-
tage and is the most sensitive. A widely-used
agent, 18F-ﬂuorodeoxyglucose (FDG), accumulates
CENTRAL ILLUSTRATION Imaging Systemic Inﬂammatory Networks in Ischemic Heart Disease
Integrated clinical datasets, including whole-body imaging, and immunological assays, such as ﬂow cytometry of blood and bone marrow, could provide insight into the
systemic immune response after acute myocardial infarction (AMI). (A) 18F-FDG PET-CT in a patient with atherosclerosis (17). (B) Inﬁltration of 99mTc-labeled leukocytes
into 18F-FDG–rich aortic lesions in the same patient (17). (C)MRI in a patient with AMI after injection of USPIO, arrows indicate infarct (57). (D) 18F-FDG PET, (E) LGE MRI,
and (F) fused image in a patient with AMI (Schwaiger, unpublished data, 2014). (G) Uptake of 18F-FDG in the bone marrow and spleen of a patient with AMI (71).
(H) Measurements obtained in the blood and bone marrow include the number and phenotype of monocytes and their progenitors. A monocyte, a PCR array of
monocytes, and a ﬂow cytometry plot of progenitor cells are shown. FDG ¼ ﬂuorodeoxyglucose; LGE ¼ late gadolinium enhancement; MRI ¼ magnetic resonance
imaging; PCR ¼ polymerase chain reaction; PET ¼ positron emission tomography; SPECT ¼ single photon emission computed tomography; 99mTc ¼ technetium-99m;
USPIO ¼ ultrasmall superparamagnetic iron oxide nanoparticles.
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1589in metabolically-active cells and can be harnessed to
image inﬂammation in cardiovascular organs, as
immune cells, particularly macrophages, internalize
18F isotope-derivatized glucose. Vascular 18F-FDG
imaging in patients with atherosclerosis robustly
correlates with macrophage density as measured by
histology (56). It is increasingly used to monitor
inﬂammation in vascular beds as a function of
therapy in patients, particularly in the aorta and
carotid arteries (60–64). 18F-FDG imaging in the
heart, that is, in coronaries or the acutely-infarcted
myocardium, is more complex, as distressed myo-
cytes rely on glycolysis and avidly ingest the agent.
Myocyte 18F-FDG uptake can be attenuated with
meals low in carbohydrates on the day before
imaging, which is routinely done for cardiac PET
imaging in patients with sarcoidosis. In mice with
AMI, the majority of infarct 18F-FDG signals de-
rive from immune cells (65). In patients, however,
macrophage-enriched ischemic tissue is more het-
erogeneously distributed than in mice after coronary
ligation. Islands of surviving myocytes interspersed
with inﬂamed necrotic areas may compound the
interpretation of 18F-FDG data. Ongoing work should
clarify these questions, and hybrid PET/CMR will
amplify our understanding of signal sources by com-
paring simultaneously acquired 18F-FDG with USPIO
data. In addition, a number of promising immune im-
aging approaches have been applied to ischemic heart
disease, including imaging integrins expressed by
leukocytes and stromal cells during angiogenesis (66),
imaging leukocyte receptors (67,68), calcium imaging
with sodium ﬂuoride (69), and ﬂuorine-19 perﬂuoro-
carbon CMR (70).
WHAT IS ON THE HORIZON FOR CLINICAL
IMAGING IN ISCHEMIC HEART DISEASE?
Several immune-targeting imaging agents are in the
pipeline, including protease reporters, PET isotope-
labeled peptides, nanoparticles, and minibodies.
These will be more speciﬁc than currently-available
agents and will increase our ability to measure the
abundance of leukocytes and their subsets, adhesion
molecules that recruit leukocytes into tissue, and
targets related to leukocyte function in cardiovascu-
lar tissues. Recently published clinical studies show
that even currently-approved tools can provide
insight into the pathophysiology of ischemic heart
disease. For instance, a SPECT/CT study in patients
with atherosclerosis (17) tracked autologous periph-
eral blood mononuclear cells to atherosclerotic pla-
ques that were also high in 18F-FDG PET signal,
implying that leukocytes migrate to inﬂamedatherosclerotic lesions in patients. Several small
18F-FDG PET/CT studies in patients with AMI
reported increased PET signals in ischemic myocar-
dial regions in association with higher 18F-FDG uptake
in remote nonculprit atherosclerotic plaque, as well
as in hematopoietic organs (39,71–73), highlighting
the systemic inﬂammation that follows organ
ischemia, as previously described in pre-clinical
models. A retrospective trial in patients with athero-
sclerosis reported that increased splenic 18F-FDG
predicts higher cardiovascular event rates (73). These
trials exemplify the opportunities generated by
whole-body imaging, including the ability to sample
more than 1 organ system. A next step could include
characterizing inﬂammatory networks, for instance,
by integrating PET data in multiple target tissues
(bone marrow, spleen, heart, plaque) with MRI
(USPIO uptake in infarct, functional data on left
ventricular wall motion) and studies of inﬂammatory
chemokines and circulating cells in blood during im-
aging (Central Illustration). In addition, targeted im-
aging of pathways that confer risk and interfere with
the immune system, such as sympathetic nervous
signaling (74), may allow us to simultaneously as-
sess information transfer between involved organ
systems.
Imaging’s recent evolution toward quantitative
reporting on leukocytes and molecules will most
assuredly accelerate the expansion of our knowledge
regarding the immune system’s role in ischemic heart
disease. Directing imaging toward this task requires
a wide range of expertise spanning hematology,
cellular immunology, clinical cardiology, isotope
physics, optical physics, and imaging hardware de-
velopment. Because no one person uniﬁes this
knowledge, multidisciplinary teams are necessary to
advance the ﬁeld. The authors of this paper formed a
collaboration (75) to focus on deciphering systemic
inﬂammatory networks in ischemic heart disease. Our
goals include the adoption of imaging for basic dis-
covery, clinical translation, and testing of immuno-
modulatory interventions in AMI.
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